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Abstract
Background: The 2002-2003 Severe Acute Respiratory Syndrome (SARS) outbreak infected 8,422 individuals leading
to 916 deaths around the world. However, there have been few epidemiological studies of SARS comparing
epidemiologic features across regions. The aim of this study is to identify similarities and differences in SARS
epidemiology in three populations with similar host and viral genotype.
Methods: We present a comparative epidemiologic analysis of SARS, based on an integrated dataset with 3,336
SARS patients from Hong Kong, Beijing and Taiwan, epidemiological and clinical characteristics such as incubation,
onset-to-admission, onset-to-discharge and onset-to-death periods, case fatality ratios (CFRs) and presenting
symptoms are described and compared between regions. We further explored the influence of demographic and
clinical variables on the apparently large differences in CFRs between the three regions.
Results: All three regions showed similar incubation periods and progressive shortening of the onset-to-admission
interval through the epidemic. Adjusted for sex, health care worker status and nosocomial setting, older age was
associated with a higher fatality, with adjusted odds ratio (AOR): 2.10 (95% confidence interval: 1.45, 3.04) for those
aged 51-60; AOR: 4.57 (95% confidence interval: 3.32, 7.30) for those aged above 60 compared to those aged 41-50
years. Presence of pre-existing comorbid conditions was also associated with greater mortality (AOR: 1.74; 95%
confidence interval: 1.36, 2.21).
Conclusion: The large discrepancy in crude fatality ratios across the three regions can only be partly explained by
epidemiological and clinical heterogeneities. Our findings underline the importance of a common data collection
platform, especially in an emerging epidemic, in order to identify and explain consistencies and differences in the
eventual clinical and public health outcomes of infectious disease outbreaks, which is becoming increasingly
important in our highly interconnected world.
Background
The 2002-2003 SARS outbreak infected 8,422 indivi-
duals leading to 916 deaths in eight affected areas [1].
The first case was identified on 16 November 2002 in
the southern Chinese city of Foshan [2]. The epidemic
then spread within Guangdong province before a large
superspreading event in Hong Kong seeded the global
outbreak [3]. On 5 July 2003, the World Health Organi-
zation (WHO) announced the last affected area Taiwan
to be transmission free and declared the last human-to-
human transmission chain successfully interrupted [4].
Hong Kong, mainland China and Taiwan carried the
largest disease burden as well as marked the most
important milestones of the global outbreak. However,
due to geo-political factors beyond the remit of public
health, a consolidated account of their collective experi-
ence has not previously been documented.
Except for a few sporadic case reports mostly invol-
ving laboratory mishaps [5-7], there has not been sus-
tained human-to-human transmission since 2003.
However, the re-emergence of SARS remains a distinct
possibility given that similar viruses continue to be iso-
lated in potential animal reservoirs including bats [8,9]
and palm civets [10], and trading of the latter continues
in Guangdong province despite its official ban [11].
Moreover, reemergence in humans could result from an
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mal host. In addition, among the three affected regions
in Greater China, the disease had apparently different
epidemiological characteristics whereas the populations
share the same gene pool and the same viral clade [12].
These apparent epidemiologic heterogeneities despite
similar host and viral genotypes as well as the prepared-
ness imperative for a possible return of SARS motivated
the present comparative analysis of the three regions,
based on an integrated database of 3336 probable cases,
which is the largest single repository of SARS patients
constructed to date. We present comprehensive esti-
mates of epidemiologic parameters of interest, and we
also investigate potential explanations for the observed
discrepancies between regions.
Methods
Sources of data
We analyzed a combined database of SARS patients
from Hong Kong (n = 1755), Beijing (n = 917) and Tai-
wan (n = 664). Clinical, demographic and epidemiologic
details for SARS patients from each region were col-
lected, coded and anonymized for analysis. All analyses
were based on patients who satisfied the WHO defini-
tion for ‘probable cases’ [13]. In Beijing, clinical presen-
t a t i o n ,e x p o s u r eh i s t o r y ,b l o o dt e s t ,c h e s tC Ta n dX - r a y
scan were also reviewed in additional to the WHO
definition.
Our database on all 1755 probable cases in Hong
Kong was derived from the Department of Health mas-
ter list and the Hospital Authority eSARS system as pre-
viously described [14].
Data on 917 of the 2521 probable cases in Beijing [15],
who were either directly admitted or transferred to Xiao
Tang Shan Hospital (XTS Hospital, n = 680), the No.
302 People’s Liberation Army Hospital (Hospital 302,
n = 111) or the No. 309 People’sL i b e r a t i o nA r m yH o s p i -
tal (Hospital 309, n = 126) were included. Clinical infor-
mation was reviewed by a panel of experts in the earlier
stage of the epidemics and furthermore a standardized
report form was used after May as previously described
[15]. Data were extracted by detailed chart review in each
hospital following a standard protocol. Hospital 309
admitted many of the earliest SARS patients and reached
full capacity by early April. SARS patients were then sent
to Hospital 302, a hospital specializing in infectious dis-
eases. The severity and infectiousness of SARS prompted
the Beijing government to build the XTS Hospital in
eight days, opening on 1 May 2003. Data on comorbid-
ities, and symptoms were unavailable for patients in
Hospital 309.
Similarly, we captured the corresponding data from all
664 probable cases in Taiwan who provided the infor-
mation through standardized screening questionnaires at
emergency rooms and on admission. Data were col-
lected from all hospitals and integrated into a dataset
officially maintained by the Centers for Disease Control,
Taiwan.
Statistical Analysis
We compared the characteristics of SARS patients by
region in terms of demographic and clinical variables such
as age, sex and health care worker (HCW) status, presence
of pre-existing comorbid conditions (including ischemic
heart disease, cerebrovascular disease, cancer, diabetes,
chronic renal failure, chronic liver disease and asthma)
and whether the patients were admitted before symptom
onset. We estimated the case fatality ratios (CFRs) within
subgroups of each of these characteristics. We calculated
the age- and sex-standardized CFRs and associated exact
binomial 95% confidence intervals based on the World
Standard Population [16]. We fitted multivariable logistic
regression models, controlled for variables such as sex,
age, health care worker status, preexisting comorbid con-
ditions and nosocomial infection, for each region on all
data allowing us to estimate the adjusted odds ratios of
mortality between regions. In the regression models we
excluded all 126 patients from Hospital 309 for whom
data on pre-existing comorbid conditions were not avail-
able and also other two, one and five patients from Hong
Kong, Beijing and Taiwan respectively with unknown age,
pre-existing comorbid conditions, onset date or admission
date. To avoid extreme values in the adjusted odds ratio
f o rt h ea g ee f f e c t ,w ec h o s et h em i d d l ea g eg r o u pa st h e
reference group. For Hong Kong patients, we also tested
t h ee f f e c to fr e s i d e n c ei nA m o yG a r d e nw h e r eas e v e r e
outbreak occurred in which many patients presented with
diarrhea [17].
Incubation period was estimated on patients with
dates of exposure to a potentially infected individual
and a symptom onset date, using both non-parametric
and parametric methods allowing for interval censoring
[18]. We plotted the epidemic curves in each region,
and examined the changes in onset-to-admission distri-
bution over the course of the epidemic.
We identified factors which might have affected the
onset-to-death and onset-to-discharge distribution and
compared the differences across the regions. The onset-
to-death and onset-to-discharge periods were firstly log-
transformed and then fitted by linear regression separately
to the same variables as in the previous model.
Finally, we examined regional differences in symptoms
at presentation. All analyses were conducted in R ver-
sion 2.3.1 [19].
Results
Additional file 1 shows patient characteristics by region
and the associated crude CFRs. Patients in Hong Kong
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Beijing (34.7 years) but younger than those in Taiwan
(47.2 years). Case fatality was consistently and strongly
age-dependent. Approximately one-third of Taiwan
SARS patients had pre-existing comorbid conditions,
which was much greater than Hong Kong (20%) and
Beijing (4%, based on available data), and in each region
the CFRs were markedly elevated for those patients with
comorbidities.
Overall, the crude CFRs differed substantially across
regions (Additional file 1). After standardizing for age
and sex, the case fatality ratios converged somewhat,
suggesting that some of the crude differences were due
to the different patient demographic profiles particularly
in patients’ ages between the three regions.
Additional file 1 also displays the adjusted odds ratios
of death for each predictor based on data from each
region. The adjusted results confirm that older age,
non-HCWs, presence of pre-existing comorbid condi-
tions and admission before symptom onset were
strongly associated with mortality. In the combined
model (Additional file 2), the adjusted odds ratios (95%
confidence intervals) of case fatality for Beijing and Tai-
wan were 0.18 (0.11 to 0.29) and 1.64 (1.29 to 2.07)
compared to Hong Kong. When the XTS Hospital
patients were excluded, the adjusted odds ratios (95%
confidence intervals) of case fatality for Beijing was 0.98
(0.46 to 2.09) compared to Hong Kong. We also fitted a
logistic regression analysis to test for any differential
effects of sex, age, health care worker status, pre-existing
comorbid conditions and nosocomial acquisition
between Hospital 302 and XTS Hospital. All the first-
order interaction effects were found to be insignificant.
All main and interaction effects with residence in Amoy
Garden were also found to be insignificant.
Data on exposure and onset times were available for
168 patients in Hong Kong, 97 patients in Beijing and
210 patients in Taiwan. Fitted lognormal distributions
showed good fit compared to non-parametric estimates
of the incubation distribution (Figure 1). Based on the
lognormal distributions, the estimated means (standard
deviations) of the incubation distributions were 4.4 days
(4.6 days) in Hong Kong, 5.7 days (9.7 days) in Beijing
and 6.9 (6.1 days) in Taiwan. The 25, 50, 75 and 95
th
percentiles were 2, 3, 5 and 12 days in Hong Kong, 1, 3,
6 and 20 days in Beijing and 3, 5, 9 and 18 days in
Taiwan.
Figure 2A shows the epidemic curve in each region,
supplemented with the overall epidemic curve in Beijing
[15]. The epidemic in Hong Kong occurred mainly in
late March and early April 2003, preceding the out-
breaks in Beijing and Taiwan by approximately one
month. Figure 2B, C and 2D show box plots of the time
from onset to admission during different calendar time
periods and the overall distributions of onset-to-admis-
sion intervals. Within each region, the onset-to-admis-
sion times decreased throughout the main part of all
three epidemics, while onset-to-admission times
appeared to increase towards the end of the Hong Kong
epidemic. Excluding the patients admitted before symp-
tom onset, the mean delay from onset to admission
were 3.6, 2.7 and 2.8 days respectively for Hong Kong,
Beijing and Taiwan. A relatively large proportion of
patients were admitted to hospital within one day after
symptom onset in both Beijing and Taiwan, and Taiwan
had a higher proportion of patients admitted before
symptom onset. In Hong Kong and Taiwan, patients
admitted before symptom onset had a much higher CFR
(53% and 70% respectively, see Additional files 3 and 4).
Hong Kong and Taiwan showed a decreasing gradient
with prolonged delay from first symptoms to hospitali-
zation until about one week whereas the opposite
appeared to be the case in Beijing. Within Beijing, there
was a clear difference in both onset-to-admission distri-
butions and CFRs among hospitals although the trends
were mostly consistent (see Additional file 4).
The median onset-to-death periods in Hong Kong, Beij-
ing and Taiwan were 21, 24 and 10 days respectively,
while the median onset-to-discharge periods were 23, 36
and 19 days respectively. We also examined factors
affecting the length of these periods (see Additional file
5). Patients in the youngest age group and those who
had acquired SARS nosocomially had significantly
shorter onset-to-death periods, while non-health care
workers and those with pre-existing comorbid condi-
tions had marginally shorter onset-to-death periods.
When comparing across the three regions, Hong Kong
and Beijing patients had similar onset-to-death periods,
but those of patients in Taiwan were significantly
shorter. As a sensitivity analysis, we show the factors
affecting onset-to-death and onset-to-discharge exclud-
ing data from XTS Hospital (see Additional file 6).
Regarding the onset-to-discharge period, younger
patients were found to have shorter lengths of stay in
hospital on average. We found statistically significant
interaction effects between HCW status and location
and between pre-existing comorbid conditions and loca-
tion, where HCWs in Taiwan had longer onset-to-dis-
charge periods (acceleration factor = 1.35, 95% CI: 1.17,
1.55), while those with pre-existing comorbid conditions
in Taiwan had shorter periods (acceleration factor =
0.87, 95% CI: 0.75, 1.02). After adjustment for the above
factors, Beijing had a significantly longer onset-to-dis-
charge period comparing with Hong Kong, while Tai-
wan had a significantly shorter period.
Figure 3 summarizes symptoms at the time of presen-
tation in Hong Kong, Beijing (Hospital 302 only) and
Taiwan. While the prevalence of the different symptoms
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most symptoms was typically higher in Hong Kong.
Fever was the most common presenting symptom in all
three regions. Dizziness, rigor, shortness of breath as
well as gastro-intestinal symptoms including diarrhea,
vomiting and abdominal pain were rarely reported in
Beijing, on the other hand every patient in Beijing
reported malaise.
Discussion and Conclusions
This set of analyses is the most comprehensive to date,
based on data accounting for 40% of the global case
load. Simultaneously analysing data from various
affected areas in Greater China together revealed
consistencies and explained heterogeneities that would
have otherwise remained unexplored. Our combined
database is unique in that of the three regions, only
mainland China is a member of the WHO whereas
Hong Kong is an observer and Taiwan is a non-mem-
ber. Such geo-political influences have posed an almost
insurmountable challenge to official supranational agen-
cies in pulling together the respective databases [20].
Database construction during an outbreak is critical to
underpin analyses that will inform policy decisions
regarding both disease control and treatment of infected
patients. Key to the utility of such databases is their
scope, format, accuracy and timeliness. While we have
largely succeeded on the first two counts, the fact that
Figure 1 Estimated incubation distribution. (A) Hong Kong (n = 168), (B) Beijing* (n = 97) and (C) Taiwan (n = 156) using a non-parametric
method (solid line) and fitted to a lognormal distribution (dashed line). (D) Comparison of estimated incubation distributions fitted to a
lognormal distribution in Hong Kong (solid line), Beijing (dashed line), and Taiwan (dotted line). *The large steps seen in the non-parametric
estimate in Beijing are aretefacts due to the small sample size.
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receded into its animal reservoir points to an urgent
deficiency in the global public health research infra-
structure. Nevertheless, this report underscores the posi-
tive steps forward in recent years.
Our findings confirm the widely reported heteroge-
neous CFRs in the three regions [1,21,22]. However, dis-
counting the highly selected XTS Hospital sample, the
Beijing CFR approximated that of Hong Kong. On the
other hand, Taiwan had a 64% higher adjusted case
fatality compared to Hong Kong. Clearly one of the
most important explanations for the observed low case
fatality ratio in our subset of patients from Beijing is the
inherent selection bias. While we studied 36% of the
reported probable SARS cases in Beijing, from three of
the largest SARS hospitals, our subset is by no means
representative. The majority (74%) of our patients were
from the XTS Hospital, a facility which was built espe-
cially to house SARS patients and opened halfway
through the epidemic. Only one of the 680 inpatients
was directly admitted, the remainder were transferred
from other hospitals in Beijing. Although some of the
Figure 2 Epidemiological characteristics in Hong Kong, Beijing and Taiwan. (A) Epidemic curve for Hong Kong, Beijing (based on our data
and those from a Beijing dataset [15]), and Taiwan. B-D*: Time from onset to admission distribution for each 2-week period and onset-to-
admission distribution for (B) Hong Kong, (C) Beijing and (D) Taiwan. * Patients admitted before symptom onset and periods with fewer than 10
cases were excluded.
Lau et al. BMC Infectious Diseases 2010, 10:50
http://www.biomedcentral.com/1471-2334/10/50
Page 5 of 9XTS patients experienced symptom onset as early as the
end of March, admission to XTS would have required
survival until at least May 1, when XTS opened. Further,
it is less likely that patients in serious condition (for
example requiring mechanical ventilation) would have
been transferred. As further confirmation of the sys-
tematic selection of the XTS sample, we found that
patients admitted to XTS Hospital were epidemiologi-
cally biased, as shown by having shorter onset-to-admis-
sion periods and longer onset-to-discharge periods (data
not shown).
An interesting related finding is that the relatively
higher CFR also applied consistently to each subgroup
including low risk groups such as younger patients and
HCWs, which suggests that the presence of some com-
mon factors not included in our models (e.g. treatment
protocols, hospital setting) may have independently
increased CFRs in Taiwan. However, the treatment of
choice in Hong Kong and Taiwan was the combined
use of ribavirin and corticosteroids [14,23], and a large
meta-analysis has shown that these treatments were
likely ineffective [24]. We also observed similar patterns
of CFRs for patients with the four most common
comorbidities (diabetes, cardiovascular disease, ischae-
mic heart disease and chronic obstructive airways
disease; data not shown) between Hong Kong and Tai-
wan and we did not observe exceptionally high case-
fatality ratios among the patients with comorbidities in
Taiwan. Hence the difference is probably not attributa-
ble to anti-viral or immunologic regimens but could
have been related to different levels of general suppor-
tive care. Overall, our analysis found that age and pre-
existing comorbid conditions were two major determi-
nants of fatality, which is consistent with existing studies
[14,25-30]. Male sex was significantly associated with
increased risk of fatality in Hong Kong after adjustment
for other important confounding factors, consistent with
a previous study in Hong Kong that identified a sex
effect in unadjusted analyses of aggregate data [31]. The
reasons for an increase in risk of death among males
remain unclear. In addition we found that admission
before symptom onset, most likely due to nosocomial
acquisition, was also significantly associated with higher
fatality rate after adjustment for comorbidities in Taiwan
[32].
In terms of epidemiologic parameters, the incubation
period had mean 4.4, 5.7 and 6.9 days and a 95
th per-
centile of 12.4, 19.7 and 17.9 days in Hong Kong, Beijing
and Taiwan respectively, with some degree of variation
between regions [18]. Together they can reliably inform
Figure 3 Proportion of cases showing different symptoms on presentation in Hong Kong, Beijing (Hospital 302 only
†)a n dT a i w a n .
* Labels on the vertical axis have been jittered for better presentation.
† Detailed symptom data were missing for Hospital 309 patients.
‡
Malaise and rigor were not documented in Taiwan.
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case and advise the public health practitioner the appro-
priate period of quarantine. While most countries used
a ten-day quarantine period, based on early estimates of
the incubation period [33], our findings suggest that a
longer period may be appropriate if SARS were to ree-
merge [29]. However differences between regions in the
incubation distribution, as well as in the onset to dis-
charge/death distributions discussed below, may be due
to different interpretations of disease onset between the
regions.
As would be expected, our results show that onset-to-
admission periods shortened throughout the epidemic
(Figure 2) as public awareness improved and public
health interventions were implemented [14,34,35]. How-
e v e r ,i nt h et h r e er e g i o n s ,t h e r ew a sn oe v i d e n c et h a t
shorter onset-to-admission period resulted in lower
fatality (see Additional file 3), possibly due to the lack of
effective treatment and that viremia only peaks after
seven to ten days [26].
Taiwan’s shorter onset-to-death distributions, indicat-
ing quicker deterioration, coupled with the consistently
higher fatality ratios for most subgroups raises the possi-
bility that the management of these patients did not
compare favorably with those in the other two regions,
especially if we assume the viral agent and host genetic
susceptibility were similar throughout. However without
more detailed clinical data, for example levels of viral
load or as a proxy lactate dehydrogenase at admission
reflecting initial illness severity [14,29], it is not possible
to discern here whether management and treatment, or
some other factors, were responsible for the higher fatal-
ity ratios in Taiwan. Alternatively, differences in envir-
onment may be responsible for some observed
differences, given the known associations between for
example smoking and respiratory disease [36,37]. The
relatively longer onset-to-discharge periods in Beijing
could likely be explained by different clinical or official
protocols [38].
Our description of the variability between regions in
symptoms at presentation (Figure 3) is the first such
comparison in the literature. The higher rates in Hong
Kong of almost every symptom could be due to differ-
ences in reporting (or asking) behavior. This again
points to the need for a universal information supply
chain, from case and symptom definitions to guidelines
in history taking and data coding, for newly emerging or
resurging diseases of supranational interest. As pre-
viously noted all three areas analyzed here shared the
identical viral strain, as well as the same ethnic gene
pool, so it is less likely that differences are due to the
infective agent or host genetic factors. Although there
are differences in the absolute rates of the various symp-
toms, we note that a previously derived clinical
prediction rule for SARS [39] has been validated on
patients from Taiwan [40].
Finally, a few limitations bear mention. As in most
previous studies [14,29,41,42], our analysis was based
on probable cases of SARS according to the WHO
definition [13] rather than laboratory confirmed cases
because the latter definition may be biased toward
i n c l u d i n gm o r es u r v i v o r s ,p a r t i c u l a r l ya m o n gt h ee a r -
lier cases [14]. Furthermore, rapid diagnostic SARS
tests were not available until fairly late in the epidemic
and had poor sensitivity for detecting the disease
[43,44]. The WHO case definitions may have been
applied differently in the three regions, or a different
percentage of probable cases might have been caused
by other pathogens, which may have led to the
observed differences. Furthermore, while SARS patients
in Beijing were classified according to the WHO defini-
tion, but a more recent detailed case review has found
that some reported ‘probable’ SARS cases may have
been misclassified [45]. We note that odds ratios
should be interpreted with caution since they may be a
poor approximation to relative risks with outcomes
that have a high prevalence. Asymptomatic and subcli-
nical infections of SARS were not considered in our
analysis, although there is strong evidence that very
few existed [46]. A final limitation is that, as previously
discussed, the Beijing patients in our database mostly
were hospitalized in XTS Hospital and were found to
be epidemiologically different from patients in other
hospitals, which makes it difficult to generalize our
results to all patients in Beijing.
Additional file 1: Characteristics of SARS patients in Hong Kong,
Beijing and Taiwan. The associated case-fatality ratios and adjusted
odds ratios (95% confidence intervals) are also reported. CFR, case fatality
ratio; AOR, adjusted odds ratio; CI, confidence interval. * Patients with
unknown age, pre-existing comorbid conditions or admission date were
excluded.
† Adjusted for sex, age, health care worker status, preexisting
comorbid conditions and nosocomial infection.
‡ Data on final outcome
were not available for 12 patients in Taiwan and were excluded for
analysis.
§ The estimates were not shown as there was not more than 2
deaths in these age groups out of a relatively large number of patients.
|| Based on the WHO World Standard Population distribution [16].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
50-S1.DOC]
Additional file 2: Characteristics of SARS patients in Hong Kong,
Beijing and Taiwan (pooled data). The associated case-fatality ratios
and adjusted odds ratios (95% confidence intervals) are also reported.
CFR, case fatality ratio; AOR, adjusted odds ratio; CI, confidence interval.
* Data on final outcome were not available for 12 patients in Taiwan and
were excluded for analysis. Patients with unknown age, pre-existing
comorbid conditions or admission date were excluded from
multivariable logistic regression models.
† Adjusted for sex, age, health
care worker status, preexisting comorbid conditions, nosocomial infection
and region.
‡ Based on the WHO World Standard Population distribution
[16].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
50-S2.DOC]
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Page 7 of 9Additional file 3: Case fatality ratio by different onset-to-admission
periods, Hong Kong, Beijing and Taiwan. CFR, case fatality ratio; CI,
confidence interval. * Excluding 16 patients with unknown admission
dates or discharge outcome.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
50-S3.DOC]
Additional file 4: Case fatality ratio by different onset-to-admission
periods in Beijing, XTS Hospital, Hospital 302 and Hospital 309. CFR,
case fatality ratio; CI, confidence interval.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
50-S4.DOC]
Additional file 5: Factors affecting the onset-to-death and onset-to-
discharge period of SARS patients in Hong Kong, Beijing and
Taiwan. CI, confidence interval. * The acceleration factor is computed as
exp(b). It indicates the relative increase (>1) or decrease (<1) in the
median time from onset of symptoms to death or discharge.
† also
adjusted for interaction between location with admission before
symptom onset.
‡ also adjusted for interaction between location with
health care worker and pre-existing comorbid conditions.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
50-S5.DOC]
Additional file 6: Factors affecting the onset-to-death and onset-to-
discharge period of SARS patients in Hong Kong, Beijing (restricted
to Hospitals 302 and 309 only and Taiwan. CI, confidence interval.
* The acceleration factor is computed as exp(b). It indicates the relative
increase (>1) or decrease (<1) in the median time from onset of
symptoms to death or discharge.
† also adjusted for interaction between
location with admission before symptom onset.
‡ also adjusted for
interaction between location with health care worker and pre-existing
comorbid conditions.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
50-S6.DOC]
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